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Despite rapidly increasing intervention, functional disability due to chronic low back pain
(cLBP) has increased in recent decades. We often
cannot identify mechanisms to explain the major
negative impact cLBP has on patients’ lives. Such
cLBP is often termed non-specific, and may be
due to multiple biologic and behavioral etiologies.
Researchers use varied inclusion criteria, definitions, baseline assessments, and outcome measures, which impede comparisons and consensus.
The NIH Pain Consortium therefore charged a
Research Task Force (RTF) to draft standards for
research on cLBP. The resulting multidisciplinary
panel recommended using 2 questions to define
cLBP; classifying cLBP by its impact (defined
by pain intensity, pain interference, and physical
function); use of a minimal data set to describe
research participants (drawing heavily on the
PROMIS methodology); reporting “responder
analyses” in addition to mean outcome scores; and
suggestions for future research and dissemination.
The Pain Consortium has approved the recommendations, which investigators should incorporate into NIH grant proposals. The RTF believes
these recommendations will advance the field,
help to resolve controversies, and facilitate future
research addressing the genomic, neurologic, and
other mechanistic substrates of chronic low back
pain. We expect the RTF recommendations will
become a dynamic document, and undergo continual improvement.

Perspective: A Task Force was convened by the
NIH Pain Consortium, with the goal of developing research standards for chronic low back pain.
The results included recommendations for definitions, a minimal dataset, reporting outcomes, and
future research. Greater consistency in reporting
should facilitate comparisons among studies and
the development of phenotypes.
KEY WORDS: low back pain; chronic low back
pain; research standards; minimum dataset; NIH
Task Force

Introduction
The Institute of Medicine recently estimated that
chronic pain affects about 100 million adults in the
United States, with an estimated annual cost of $635
billion, including direct medical expenditures and
loss of work productivity.(3) Activity-limiting low
back pain (LBP), in particular, has a world-wide
lifetime prevalence of about 39% and a similar annual prevalence of 38%.(61) The majority of people
having LBP experience recurrent episodes.(62) The
use of all interventions for treating chronic LBP
(cLBP) increased from 1995–2010, including surgery, pharmacological, and non-pharmacological
approaches. Despite increased utilization, however,
the prevalence of symptoms and expenditures has
increased.37,70,91

†Reprinted

with permission: Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, Carragee E, et al. Report of
the NIH Task Force on research standards for chronic low back pain. J Pain. 2014;15(6):569–85.
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There is growing evidence that cLBP, like other
chronic pain conditions, can progress beyond a
symptomatic state to a complex condition unto
itself,(109) involving persistent anatomical and functional changes in the central nervous system(9,93,100)
in addition to structural changes in the back (e.g.,
degenerative spinal changes, atrophy or asymmetry of
para-spinal muscles).(10,11,14) Although some patients
with cLBP may have clear pathoanatomic etiologies,
for many there is no clear association between pain
and identifiable pathology of the spine or its associated soft tissues.26
Many patients who undergo procedures intended to
correct the putative causative pathoanatomy continue
to have pain. Furthermore, we often cannot identify
mechanisms to account for the substantial negative
impact cLBP has on the lives of many patients.(20)
Such cLBP is often termed non-specific, idiopathic,
mechanical, or due to instability, and may in fact be
due to the contributions of different and multiple
biologic and behavioral etiologies in different individuals.(87)
Many classes of interventions have been developed and tested in adults with cLBP. These include
spine surgery, injections, medications, psychological
interventions, manual therapies, exercise, nutritional
supplements, and lifestyle change and self-management approaches.(17-20) Many of these have shown
some clinical benefit, but few appear to consistently
provide substantial, long-term reductions in pain with
increased function.(25,27-29)
A critical issue for advancing research on cLBP
is comparing results from the many classes of interventions. In 2009 and 2010, the National Institutes
of Health (NIH) Pain Consortium convened two
workshops on LBP research, inviting experts from
the relevant scientific and clinical fields to provide research recommendations to NIH. These experts noted
that clinical studies have used variable inclusion and
exclusion criteria, case definitions for LBP chronicity or recurrence, baseline assessments, stratification
criteria, and outcome measures. As a result, it is difficult to compare epidemiological data and studies of
similar or competing interventions, replicate findings,
pool data from multiple studies, resolve conflicting
conclusions, develop multidisciplinary consensus, or
even achieve consensus within a discipline regarding
interpretation of findings. Key recommendations from
the workshops on how to advance cLBP research were
to establish research standards on cLBP, and to have
NIH facilitate this process.
In response, the NIH Pain Consortium established
a Steering Committee for a Research Task Force
(RTF) on Research Standards for cLBP. The Steering Committee was comprised of representatives
from the following NIH institutes/centers: National
Center for Complementary and Alternative Medicine
(NCCAM), National Institute on Aging, National
Institute of Arthritis, Musculoskeletal, and Skin

Diseases (NIAMS), National Institute of Child Health
and Human Development, National Institute on Drug
Abuse, National Institute of Dental and Craniofacial
Research, National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of
Nursing Research. The Steering Committee developed goals for the RTF, identified the needed scientific
and clinical expertise, selected two co-chairs, and
invited 14 additional experts from outside NIH to
comprise the RTF. The Steering Committee provided
two representatives (Drs. Panagis and Khalsa) in exofficio (i.e., non-voting) capacity to the RTF.
The charge by the NIH Pain Consortium to the RTF
was to develop a set of standards for clinical research
on cLBP that would address the following:
●

●

●
●

●

Consider the state of existing research relevant to
the development of standards for clinical research
on cLBP
Conduct a comprehensive review of existing
case definitions, diagnostic criteria, and outcome
measures that are relevant for clinical research
on cLBP
Develop a draft set of standards for research
on cLBP
Engage the broader research community and
representatives from relevant government agencies in developing these standards for research
on cLBP
Chart a general plan for their incorporation into
research studies and their future modification

This charge focused solely on developing standards
for research, and not for use in coding, billing, or
general use in clinical settings.

Methods
Creating the RTF
The Steering Committee selected two co-Chairs
with complementary leadership expertise. Dr. Deyo
was chosen for his expertise in LBP research and
Dr. Dworkin for his prior leadership in developing
Research Diagnostic Criteria for another chronic pain
condition, temporomandibular disorders. The coChairs in consultation with the Steering Committee
selected the RTF members for the needed scientific
and clinical expertise (Table 1).

Work Plan
The Task Force evolved a three-stage work plan,
each with a two-day meeting.

Stage 1
The first meeting opened with remarks by the
NIAMS and NCCAM Directors, Stephen Katz,
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Table 1. Task Force Members, Affiliations, and Expertise
Members

Affiliations

Expertise

Co-Chairs
Richard A. Deyo
MD, MPH

Departments of Family Medicine, Internal Medicine, and Public
Health, Oregon Health and Science University and Clinical
Investigator, Kaiser Center for Health Research

Primary care, Health Services
Research

Samuel F. Dworkin
DDS, PhD

Departments of Oral Medicine and Psychiatry and Behavioral
Sciences, University of Washington

Temporomandibular joint disorders,
chronic pain, clinical psychology

Gunnar Andersson
MD, PhD

Department of Orthopaedic Surgery, Rush University Medical
Center

Orthopaedic spine surgery

David Borenstein MD

Department of Rheumatology, George Washington University

Rheumatology

Eugene Carragee MD

Department of Orthopaedic Surgery, Stanford University School
of Medicine

Orthopaedic spine surgery

John Carrino MD,
MPH

Department of Radiology, Johns Hopkins University School of
Medicine

Musculoskeletal radiology

Roger Chou MD

Departments of Medicine, and of Medical Informatics and Clinical General Internal Medicine,
Epidemiology, Oregon Health and Science University
Systematic Review

Anthony DeLitto PT, PhD

Department of Physical Therapy, University of Pittsburgh
School of Health Rehabilitation

Physical Therapy

Christine Goertz DC, PhD

Palmer College of Chiropractic

Chiropractic care, Epidemiology

John Loeser MD

Department of Neurological Surgery, University of Washington

Neurosurgery, pain management

Sean Mackey MD, PhD

Department of Anesthesia, Stanford University School of
Medicine

Pain Management, Functional Brain
Imaging

James Rainville MD

Physical Medicine and Rehabilitation, New England Baptist
Hospital and Tufts University

Spine rehabilitation

Tor Tosteson ScD

Department of Community and Family Medicine, Dartmouth
University

Biostatistics

Dennis Turk PhD

Department of Anesthesiology and Pain Medicine, University of
Washington

Pain medicine, Psychology

Michael Von Korff ScD

Group Health Research Institute, Seattle

Epidemiology

Debra K. Weiner MD

Geriatric Research, Education and Clinical Center, VA Pittsburgh
Healthcare System and the Departments of Medicine, Psychiatry,
and Anesthesiology; the Clinical and Translational Science
Institute, University of Pittsburgh

Geriatric Medicine,
Rheumatology

Task Force Members

MD, PhD and Josephine Briggs, MD, respectively.
The directors emphasized the nature of chronic
back pain as a highly prevalent and costly public
health challenge. They noted the existence of many
stakeholders, including individuals with back pain,
health care systems, clinicians, drug and device makers, federal, state, third-party payers, and regulatory
agencies. They emphasized the research focus of
the Task Force as opposed to a focus on clinical or
administrative concerns.
Initial efforts of the RTF were directed at defining
subsequent activities and products. At the initial and
subsequent meetings, a consensus evolved on several
important issues and strategies (Table 2).
The RTF noted that intended users of the proposed
research standards would be investigators submitting

grant applications to NIH, but that the standards
would be available and encouraged for all researchers. The research standards could potentially allow
cLBP phenotypes to be uncovered, based on physical
and psychosocial findings.
The RTF decided that it could not respond in
detail to every component of the NIH Pain Consortium’s charge. For example, producing explicit
evidence-based diagnostic criteria for conditions
such as spinal stenosis, sciatica, or spine “instability” would be impossible with available time and
resources, given the current lack of professional
consensus. However, stratifying cLBP by its impact might have equally important descriptive and
prognostic value, and could supplement any pathophysiologic description.
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Table 2. Key Principles Developed by the Task Force on Research Standards for Chronic Low Back Pain
1. The process should use an evidence-based approach that incorporates a biopsychosocial model of chronic pain.
2. Data should be useful for a wide range of conditions, including patients thought to have degenerative spinal disorders (e.g. herniated
disc or lumbar stenosis) as well as those without identified pathoanatomy.
3. Patients with underlying systemic or highly specific diseases were not the target of the Task Force. Such conditions include cancer,
spinal infections, fractures, and inflammatory spondylopathies such as ankylosing spondylitis.
4. Patients with no identified pathoanatomy should not be assumed to have “psychological”, “psychosomatic”, “psychogenic”, or
“somatoform” pain.
5. Given the current state of knowledge, stratifying chronic back pain by its impact is more feasible and potentially useful than
attempting classification solely by pathoanatomy or pathophysiology. Impact will tentatively be defined in terms of pain intensity,
interference with activities, and physical function.
6. A minimal uniform dataset should be reported in all studies of chronic back pain. This should be brief, so that investigators can
supplement it with key measures for specific research questions.
7. The dataset should be relevant for population, observational, and interventional research.
8. The dataset should include both biomedical and psychosocial variables.
9. An investigator could substitute more detailed, precise, and well-validated measures for a particular domain, but should report data
for each domain of the minimal dataset.
10. Additional “core” items would be recommended for specific study aims or populations, such as surgical trials or elderly
populations.
11. A prognostic dimension for the classification of chronic low back pain would be desirable, but more evidence is needed before an
explicit recommendation will be made.
12. Research standards should evolve, and the RTF will suggest a potential research agenda for refining the research standards.

Stage 2
The co-chairs conducted a series of surveys of
RTF members by email. The surveys addressed key
issues from Meeting 1, and were based on item lists
generated at the first RTF meeting. The surveys and
literature review efforts were as follows:
1. Survey of candidate objective findings and
medical history for a minimal dataset: Members ranked the importance of potential baseline descriptors for patients with cLBP. These
included items of medical history, comorbidity,
physical examination, and laboratory and imaging tests.
2. Survey of candidate self-report measures of
behavior, mood, and symptoms: Task Force
members were asked to rank the importance of
measures of pain-related behavioral, emotional
and psychosocial domains influencing the expression of cLBP.
3. Survey on Feasibility of Developing Research
Diagnostic Criteria for subsets of non-specific
Chronic Low Back Pain: Part of the charge from
the Pain Consortium was to consider developing a
Research Diagnostic Classification system based

on pathophysiologic or etiologic features (i.e.,
criteria for subsets of non-specific cLBP). This
survey asked Task Force members to assess the
feasibility of such an effort.
4. Review of Existing Literature on Back Pain
Classification and Prognosis: The Task Force
did not undertake a systematic literature review,
but considered previous work on back pain
taxonomy,(4,6,15,24,33,34,44,52,56,74,79,83,101,104,105,117)
prognostic classification,(13,19,31,38,39,43,48,49,53,54,
57-60,66-68,73,76,80,82,85,86,97,106,108,110,112-116,122)

pain and psychosocial measures, (12,31,42,45,64,
65,69,71,75,77,78,81,90,94,96,103,107,115,118-121,125) and
outcome assessment.(5,8,21,23,32,36,40,41,50,51,55,88,
89,95) This literature informed the deliberations
and recommendations.
At the second RTF meeting, the most highly ranked
candidate items for the minimum data set based on
survey responses were accepted with minimal disagreement or need for further discussion. Special attention was directed to the possible use of the Patient
Reported Outcomes Measurement Information System
(PROMIS) measures.(5,21,51,55,89,95) Progress was made
toward defining cLBP and its impact. There was general
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agreement that developing pathophysiologic diagnostic
criteria for subsets of non-specific low back pain was
unfeasible at present.
The RTF also heard presentations of two related
NIH efforts. The first was the NINDS effort to create
“Common Data Elements” for use by all Institutesupported researchers. The second related to the
NIH PROMIS effort, which includes several psychometrically sound patient reported outcomes measures
directly relevant to the Task Force.

Stage 3
At the third meeting, the RTF agreed on a series
of recommendations to be forwarded to the NIH Pain
Consortium. These included a definition of cLBP and
specific measures to stratify its impact. It also reached
agreement on recommending specific domains and
items to be integrated into a minimal dataset for
research on cLBP. There followed a discussion of
outcome measures and future research needs regarding the Task Force recommendations.
The Task Force also suggested strategies for
obtaining feedback and support for its recommendations. These included consultation with the NIH
Pain Consortium and relevant NIH institutes, other
government agencies, and relevant journal editors.
It would also include presentations at meetings of
research and professional organizations.

TASK FORCE RECOMMENDATIONS
The principles articulated in Table 2 led the Task
Force to several specific recommendations that are
summarized in Table 3. The rationales for these recommendations are discussed below. The first three
recommendations refer to the questionnaire instrument in Table 4.

Recommendation 1. Describe the Chronicity of
Low back Pain
The RTF recommended that “chronic low back
pain ” (cLBP) be defined as a back pain problem
that has persisted at least 3 months, and has resulted
in pain on at least half the days in the past 6 months.
A human figure drawing would illustrate the region
defined as the low back, indicating the space between
the lower posterior margin of the rib cage and the
horizontal gluteal fold (Table 4).
The RTF considered definitions based on time with
pain, days with pain, severity of pain, and varying
durations of pain. Minimal durations of 3 months
or 6 months were considered, and the problem of
intermittent symptoms was considered.
The RTF concluded that two questions should
define chronicity (Questions 1 and 2 in Table 4):
(1) “How long has back pain has been an ongoing

Table 3. Task Force Recommendations: Research Standards for Chronic Low Back Pain (cLBP)
1. Defining the chronicity of cLBP: The RTF recommended 2 questions to achieve the definition of chronic (Questions 1 and 2 in Table
4): (1) How long has back pain has been an ongoing problem for you? (2) How often has low-back pain been an ongoing problem for
you over the past 6 months? A response of greater than three months to question 1, and a response of “at least half the days in the past
6 months” to question 2 would define cLBP.
2. Stratify cLBP by impact: “Impact” was defined by pain intensity, pain interference with normal activities, and functional status. These
items have major prognostic and discriminatory importance. Impact is calculated from 9 items of the 29-item PROMIS short form
(marked with asterisks in Table 4).
3. Report a Minimum Data Set: A minimal data set is recommended for describing subjects in all research on cLBP (Table 4).
Medical history included demographics, involvement in workers compensation, work status, education, comorbidity, and previous
treatment. Physical examination items were reserved for studies of invasive interventions or of older adults. MRI was recommended
for studies of surgical interventions. Key self-report domains were pain intensity, pain interference, physical function, depression,
sleep disturbance, and catastrophizing. The short form PROMIS measures were recommended as offering the best trade-off of length
with psychometric validity.
4. Outcome Measures: Many parts of the minimum data set, such as PROMIS measures, are also appropriate as outcome measures.
However, primary outcomes of clinical studies will vary, depending on study aims, and investigators are referred to earlier consensus
documents on outcome measures. The RTF recommended reporting a “responder” analysis in addition to reporting mean scores of
outcome measures.
5. Research on the proposed standards The RTF recommended new research to improve prognostic stratification of patients
with chronic low back pain; refine and test composite outcome measures for increasing the clinical importance of study
results; undertake patient stakeholder assessment of relevant outcomes; and further evaluate psychometric properties of the
minimal dataset.
6. Dissemination: With adoption of recommendations by the NIH Pain Consortium, the RTF recommends dissemination to the broad
research community. This would include publication of a report in multiple professional journals and presentations at professional
meetings.
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Table 4. Recommended Minimum Dataset
(PROMIS items marked with 1; STarT Back or nearly identical items marked with 2; RTF Impact Classification items marked with *).

1.

How long has low-back pain been an ongoing problem for you?
 Less than 1 month
 1–3 months
 3–6 months
 6 months–1 year
 1–5 years
 More than 5 years

2.

How often has low-back pain been an ongoing problem for you over the past 6 months?
 Every day or nearly every day in the past 6 months
 At least half the days in the past 6 months
 Less than half the days in the past 6 months

3.

In the past 7 days, how would you rate your low-back pain on average?*1,2
¨
1

¨
2

¨
3

¨
4

¨
5

¨
6

¨
7

¨
8

¨
9

No pain

¨
10
Worst
Imaginable
pain

4.

Has back pain spread down your leg(s) during the past 2 weeks?2
 Yes
 No
 Not sure

5.

During the past 4 weeks, how much have
you been bothered by …

Not bothered at all

Bothered a little

Bothered a lot

•

Stomach pain

¨

¨

¨

•

Pain in your arms, legs, or joints other
than your spine or back

¨

¨

¨

•

Headaches

¨

¨

¨

•

Widespread pain or pain in most of
your body

¨

¨

¨

6.

Have you ever had a low-back operation?
 Yes, one operation
 Yes, more than one operation
 No

7.

If yes, when was your last back operation?
 Less than 6 months ago
 More than 6 months but less than 1 year ago
 Between 1 and 2 years ago
 More than 2 years ago
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8.

Did any of your back operations involve a spinal fusion? (also called an arthrodesis)
 Yes
 No
 Not sure

PAIN INTERFERENCE
In the past 7 days…

Not at all

A little bit

Somewhat

Quite a bit

Very much

How much did pain interfere with
your day-to-day activities?*1

¨

¨

¨

¨

¨

10. How much did pain interfere with
work around the home?*1

¨

¨

¨

¨

¨

11. How much did pain interfere with
your ability to participate in social
activities?*1

¨

¨

¨

¨

¨

12. How much did pain interfere with
your household chores?*1

¨

¨

¨

¨

¨

9.

13. Have you used any of the following treatments for your back pain? (Check all that apply)
•

Opioid painkillers (prescription medications such as Vicodin, Lortab,
Norco, hydrocodone, codeine, Tylenol #3 or #4, Fentanyl, Duragesic,
MS Contin, Percocet, Tylox, OxyContin, oxycodone, methadone, tramadol,
Ultram, Dilaudid)

If you checked yes, are you currently using this medication?………………………….

Yes

No

Not sure

¨

¨

¨

¨

¨

•

Injections (such as epidural steroid injections, facet injections)
……………..

¨

¨

¨

•

Exercise therapy………………………………………………………………

¨

¨

¨

•

Psychological counseling, such as cognitive-behavioral therapy……………

¨

¨

¨

The next two questions are for people who normally work outside the home.
14. I have been off work or unemployed for 1 month or more due to low-back pain.
 Agree
 Disagree
 Does not apply
15. I receive or have applied for disability or workers’ compensation benefits because I am unable to work due to
low-back pain.
 Agree
 Disagree
 Does not apply
PHYSICAL FUNCTION
Physical Function

Without any
difficulty

With a little
difficulty

With some
difficulty

With much
difficulty

Unable
to do

16. Are you able to do chores such
as vacuuming or yard work?*1

¨

¨

¨

¨

¨

17. Are you able to go up and down
stairs at a normal pace?*1

¨

¨

¨

¨

¨

18. Are you able to go for a walk of
at least 15 minutes?*1,2

¨

¨

¨

¨

¨

19. Are you able to run errands
and shop?*1

¨

¨

¨

¨

¨
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DEPRESSION
In the past 7 days...

Never

Rarely

Sometimes

Often

Always

¨

¨

¨

¨

¨

21. I felt

helpless1

¨

¨

¨

¨

¨

22. I felt

depressed1

¨

¨

¨

¨

¨

23. I felt

hopeless1

¨

¨

¨

¨

¨

Very poor

Poor

Fair

Good

Very good

¨

¨

¨

¨

¨

Not at all

A little bit

Somewhat

Quite a bit

Very much

¨

¨

¨

¨

¨

¨

¨

¨

¨

¨

¨

¨

¨

¨

¨

20. I felt worthless1

SLEEP DISTURBANCE
In the past 7 days…
24. My sleep quality was1
In the past 7 days…
25. My sleep was

refreshing1

26. I had a problem with my sleep1
27. I had difficulty falling

asleep1

28. It’s not really safe for a person with my back problem to be physically active.2
 Agree
 Disagree
29. I feel that my back pain is terrible and it’s never going to get any better.2
 Agree
 Disagree
30. Are you involved in a lawsuit or legal claim related to your back problem?
 Yes
 No
 Not sure
In the past year:
Never

Rarely

Sometimes

Often

31. Have you drunk or used drugs more than you meant to?

¨

¨

¨

¨

32. Have you felt you wanted or needed to cut down on your
drinking or drug use?

¨

¨

¨

¨

33. Age: _____ years (0–120)
34. Gender:
 Female
 Male
 Unknown
 Unspecified
35. Ethnicity: (“X” ONLY one with which you MOST CLOSELY identify)
 Hispanic or Latino
 Not Hispanic or Latino
 Unknown
 Not Reported
36. Race: (“X” those with which you identify)
 American Indian or Alaska Native
 Asian
 Black or African-American
 Native Hawaiian or Other Pacific Islander
 White
 Unknown
 Not Reported
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37. Employment Status:
 Working now
 Looking for work, unemployed
 Sick leave or maternity leave
 Disabled due to back pain, permanently or temporarily
 Disabled for reasons other than back pain
 Student
 Temporarily laid off
 Retired
 Keeping house
 Other, Specify:_________________
 Unknown
38. Education Level: (select the highest level attained)
 No high school diploma
 High school graduate or GED
 Some college, no degree
 Occupational/technical/vocational program
 Associate degree: academic program
 Bachelor’s degree
 Master’s degree (e.g., M.A., M.S., M.Eng., M.Ed., M.B.A.)
 Professional school degree (e.g., M.D., D.D.S., D.V.M., J.D.)
 Doctoral degree (e.g., Ph.D., Ed.D.)
 Unknown
39. How would you describe your cigarette smoking?
 Never smoked
 Current smoker
 Used to smoke, but have now quit
40. Height: _____
Weight: ____

¨ inches

¨ centimeters

¨ measured

¨ self-reported

¨ pounds

¨ kilograms

¨ measured

¨ self-reported

problem for you?” (2) “How often has low-back
pain been an ongoing problem for you over the past
6 months?” A response of greater than three months
to question 1, and a response of “at least half the
days in the past 6 months” to question 2 would define
cLBP. A patient with pain on at least half the days in
the past 6 months would have accumulated at least
three months worth of pain days, and the Task Force
concluded that this would be the recommended definition. It was decided that pain severity would not be
part of the definition of cLBP.

Recommendation 2. Stratify chronic low back
pain by impact
“Impact” was defined by pain intensity, pain interference with normal activities, and functional status,
using nine items of the 29-item PROMIS short form
(marked with asterisks in Table 4).
The RTF overwhelmingly agreed that neither adequate data nor resources were available to offer a new
pathoanatomic or pathophysiologic subclassification
of cLBP that was clearly superior to those currently
available. Rather, the RTF recommended stratification
of cLBP by the personal impact of low back pain.
“Impact” was proposed as a combination of pain

intensity, pain interference with normal activities,
and functional status. These items have substantial
research support to validate their discriminatory and
prognostic importance.(13,19,31,38,39,43,47-49,53,54,57-60,66-

68,73,76,80,82,85,86,97,106,108,110,112-116,122)

This stratification of cLBP by impact would be
appropriate whether or not there appears to be contributory degenerative pathoanatomy. Even when
pathoanatomic conditions are thought to contribute
to symptoms and dysfunction, they often coexist and
overlap, and sometimes fail to respond to specific
interventions. Thus, the stratification of impact seems
to be a useful addition to pathoanatomic, physiologic,
or symptomatic classification, but not a substitute.
After considerable discussion about formal prognostic scales for stratification, such as the Subgroups
for Targeted Treatment (STarT) Back instrument,(60)
the RTF decided there remained substantial uncertainty about generalizability to subspecialty patients
and older adults. Thus, the RTF recommended
further research in this area, and included several
items of the STarT Back instrument in the minimal
dataset, but chose not to require them for stratification purposes.
The recommended RTF Impact Stratification approach uses the raw PROMIS scores with the usual
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scoring of the Physical Function items is reversed.
Thus, for each item in the Impact Stratification, a
score of 1 is least severe and 5 most severe. The
exception is the single item on pain intensity, which
ranges from 0 (least severe) to 10 (most severe). Thus,
scores on the nine PROMIS-based items yielding
Impact Stratification range from 8 (least impact) to
50 (greatest impact). Items in Table 4 with an asterisk
comprise the Impact Stratification score.
Because the proposed impact score is a novel combination of three constructs (pain intensity, interference, and function), the RTF undertook a preliminary
assessment of its validity and performance, with the
assistance of PROMIS investigators. The validation
made use of existing PROMIS data from a group
of patients with LBP, with or without leg pain, who
underwent epidural steroid injections. This analysis
was covered by an existing Institutional Review
Board approval from the University of Washington.
Given the intervention, an improvement in average
functional scores was expected.
The sample included 218 patients with a mean
age of 54 years; 56% were females. There were 41%
employed full or part time, 22% retired, and 12%
receiving disability compensation, with the remainder being homemakers, students, or unemployed.
The racial mix included 87% white, 3.8% African
American, 4% American Indian, and 5% Asian or
Pacific Islander. There were 46% with a college or

more advanced degree, and 5% with less than a high
school diploma.
The data set included legacy measures of back
pain-related physical function: the Roland and Morris Disability Scale and the Oswestry Disability
Index (collected at baseline only). The RTF Impact
Stratification showed strong correlations with legacy
measures. Furthermore, score changes on the RTF
Impact Stratification correlated more strongly with
patient satisfaction at follow-up than did change on
the Roland-Morris score (Table 5).
In this rather severely affected sample, baseline
RTF Impact scores were almost equally distributed
among mild, moderate and severe impacts. Although the cutoffs used in Table 5 for mild, moderate, and severe scores were deemed as potentially
useful by the RTF, they are relatively arbitrary.
Simply reporting actual scores is recommended,
along with any categorization that investigators
may choose.
Scores on the Impact Stratification measure for this
sample improved over time, as expected. Measures
of effect size and standardized response mean for the
170 patients available for 3-month follow-up suggested that the RTF Impact Stratification was more
responsive than the Roland-Morris Disability Scale
(Table 3).
The Task Force found the results encouraging but
acknowledges that the analyses reported reflect only

Table 5. Performance of the Research Task Force Impact Stratification Among 218 Subjects Undergoing Epidural Steroid Injections;
Three‑Month Follow-Up Was Available for 170 of These Subjects (78%)
Construct validation: correlation of RTF Impact Stratification with
Legacy measures of physical function, baseline (Spearman R)

Oswestry Disability Index

Roland-Morris Disability
Questionnaire

.806

.661

Change, Roland- Morris Disability
Questionnaire

Change, RTF Impact
Stratification score

.148

.251

Baseline (N=218),
% of subjects

Follow-up (N=170),
% of subjects

RTF Impact stratification score 8-27 (mild)

30%

63%

RTF Impact stratification score 38-34 (moderate)

34%

18%

RTF Impact stratification score ≥35 (severe)

36%

19%

Mean RTF Impact stratification score (SD)

32 (8.3)

25 (9.7)

Effect Size
(Change/Baseline SD)

Standardized Response Mean
(Change/SD of change)

RTF Impact Stratification

0.69

0.75

Roland-Morris Disability Questionnaire

0.39

0.41

RTF Impact Stratification score
Construct validation: correlation of score changes with patient
satisfaction with treatment at follow-up (Spearman R, absolute value)
Patient satisfaction index, scored 1-4
Distribution of RTF Impact Stratification scores

Responsiveness
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an initial assessment. As suggested in the recommendations below for future research, further assessment
of the reliability, validity and clinical utility of this
stratification strategy is a high priority.

Recommendation 3. Report a Minimum Dataset
A minimal data set is recommended for describing
individuals participating in all research studies on
cLBP (Table 4); the minimum data set includes items
of demographics, medical history, and self-report of
symptoms and function.

Medical history, physical examination,
diagnostic testing
In the survey of RTF members regarding items for a
minimal dataset, the most highly ranked items of medical history and examination included demographics,
involvement in workers’ compensation or legal claims,
work status, education, various measures of comorbidity, and previous treatment history. For many of these
measures, the RTF adopted the format of the Common
Data Elements system implemented by the NINDS
(http://www.commondataelements.ninds.nih.gov).
The key comorbid conditions were judged to be
smoking status, obesity, substance abuse, and widespread pain symptoms. The two-item conjoint scale
(TICS) was judged to be an adequate and suitably
brief screen for substance abuse.(18) The key items
of treatment history were thought to be history of
surgical interventions and use of opioid analgesics.
Measures from the physical examination ranked
lower than items of medical history. However, the
most highly ranked of these were straight leg raising
for patients with leg pain; hip internal rotation as a
screen for hip arthritis (a potential cause of LBP); and
lower extremity strength. There was general agreement that such physical examination items could be
reserved for studies of invasive interventions (straight
leg raising and lower extremity strength) or of older
adults (hip examination). Thus, physical examination
measures would not be required of all epidemiological
studies, for example.
No laboratory or imaging tests were highly ranked,
because of the widely recognized weak association
between degenerative spine changes on imaging and
patient symptoms or function.(26) However, magnetic
resonance imaging (MRI) was considered the most
valuable of potential tests, and there was agreement
that this should be required in studies of surgical
interventions.
Self-report of functional status, psychosocial
factors, and mood disturbance
With regard to other self-report measures, there
was discussion first about the domains to be included,
then potential sources of items, then the desirable
number of items. The key domains were judged to be
physical function, depression, sleep disturbance, and

catastrophizing. The Task Force felt these constructs
were important for a wide range of patients with
chronic back pain, with or without specific pathoanatomic diagnoses. For parsimony, other important
constructs, such as anxiety, fatigue, and satisfaction
with social role were considered, but not included in
the minimal data set.
Although the Minimal Dataset in Table 4 is recommended for inclusion in all NIH-funded research
on cLBP and is available for use by all researchers, the RTF did not in any way intend to constrain
investigators regarding the scope of their proposed
scientific inquiries. On the contrary, the RTF believes
the minimal data set represents a major advance towards standardization of research reporting by asking
researchers to include, at a minimum, a set of items
that evidence supports as critical to scientifically
advancing our understanding of cLBP.
After considering several potential instruments
for assessing these domains, the RTF concluded that
the short-form PROMIS measures(1) offered the best
trade-off of length with psychometric validity for
a minimal dataset. Therefore, it recommended use
of the relevant scales from the 29-item PROMIS
short-form, which includes 4 items for each domain.
Investigators and patient samples with access to Computer Adaptive Testing could use the entire PROMIS
item bank to measure the domains included on the
PROMIS 29 Profile version 1.0, an acceptable or even
preferable alternative.(22)
There was agreement that if investigators preferred
well-validated, lengthier legacy measures of these
domains, that would be acceptable. For example, if
investigators wanted more extensive legacy measures of physical function, they might substitute the
Oswestry or Roland-Morris disability scales for the
PROMIS physical function items. If they wanted
legacy measures of depression, they might substitute
the Patient Health Questionnaire (PHQ-9)(76) or Beck
Depression Inventory.(12) In Table 4, we have labeled
the PROMIS constructs to facilitate such substitution
if desired, though investigators may wish to remove
the labels when using the dataset. If such substitutions
are made, all the other recommended domains should
still be assessed.
Investigators may find it useful to consult the
website PROsetta Stone, supported by NCI-funded investigators at Northwestern University (www.prosettastone.org).(2) This website provides a “cross-walk”
between scores on the PROMIS measures and scores
on several “legacy” measures, such as the Brief Pain
Inventory,(31) the Center for Epidemiologic Studies
Depression Scale (CES-D),(90) the PHQ-9,(77) and the
SF-36.(120) The resulting proposed Minimal Dataset
is presented in Table 4. PROMIS items are identified
with a superscript 1, and STarT Back items (or very
similar items) are identified with a superscript 2.
The RTF was able to obtain IRB approval at
Stanford University (RTF member Sean Mackay,
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Principal Investigator) to conduct an internet survey
of back pain patients using the RTF recommended
version of the Minimal Dataset. This cross-sectional
sample was distinct from the patients described
above for validity testing, who underwent intervention and follow-up. There were 221 participants
recruited from the San Francisco Bay Area using
high-visibility ads. Participants had a mean age of
46.2 years (range, 19-81), with 53% females. Participants included 72% whites; 17% Asians; 7% African
Americans, and 3.8% each of American Indians and
Pacific Islanders. There were 52% with at least a
bachelor’s degree and only a single participant with
no high school diploma. Thirty-nine percent were
employed, 5% retired, and 16% described themselves as disabled. Thirty-eight percent described
leg pain in addition to back pain, and the mean pain
intensity (on a 0-10 scale) was 5.5. In this sample,
the median time-to-completion was 7 minutes, and
75% of subjects completed the questionnaire in less
than 10 minutes.

Proposed supplemental data for specific
situations
For studies of invasive therapies such as spine
surgery, the RTF recommended that physical examination and imaging data be added to the minimal data
set. Straight leg raising, lower extremity reflexes,
and lower extremity strength as indicators of radiculopathy were recommended as a minimum physical
examination. Lumbar MRI was recommended in such
studies as the minimal imaging evaluation.
In older adults, there is increased likelihood of hip
osteoarthritis contributing to low back pain. Thus, for
studies of adults mainly over age 65, the Task force
recommended testing internal hip rotation, to help
screen for potential osteoarthritis. A screen for cognitive function may also be important in such studies,
as dementia may impair the validity of assessments
or of consent for research.
In studies focused on behavioral or mood correlates
of cLBP, the RTF recommended that investigators
be free to incorporate additional measures. These
might include, for example, assessment of emotional
status, physical function and pain behaviors, substance abuse, interpersonal violence, or quality of life
relevant to specific study interests. Such measures
should have published reliability, validity, and responsiveness data at least equal to those of the minimal
dataset’s PROMIS short-form items. These additional
measures should have population-based normative
data to be included when relevant. The IMMPACT
statement can be recommended as a starting point for
selection of desired supplemental measures.(9)
Recommendation 4. Outcome measures
Investigators are referred to earlier consensus documents on outcome measures.(16,35,40) However, the RTF

recommends reporting a “responder” analysis in addition to reporting mean scores of outcome measures.
The RTF recognized that many parts of the baseline
minimum data set, such as the PROMIS measures,
were highly appropriate as outcome measures, remembering that the initial focus of the NIH PROMIS
effort was on patient reported outcomes. It was also
recognized that the primary outcomes of clinical studies would vary, depending on study aims. For example, some might focus on pain relief, but others might
focus on return to work, physical function, mood, or
need for subsequent therapy. Thus, the RTF did not
make a recommendation regarding a minimal outcome dataset, beyond recommending consideration
of the minimal data set for standardized recording of
both baseline assessment and outcomes evaluation.
Investigators are referred to earlier consensus statements on outcome measures for studying chronic pain
in general or back pain in particular.(16,35,40)

Reporting of outcomes
An important discussion centered on reporting of
outcomes. There was a general agreement that for (at
least theoretically) continuous measures, such as pain
or function, not only should mean scores and score
changes be reported, but the proportion of participants
achieving certain thresholds should be reported. For
example, the proportion achieving a pre-specified
minimal clinically important change might be reported. Investigators have proposed minimally important
differences in PROMIS short forms, at least in the
context of cancer therapy.(123) Calculating the percent
of study participants who achieve such landmarks is
referred to by the FDA as a “responder” analysis.(84)
Other expert panels have suggested, for example,
that a 30% improvement in pain or function might be
a clinically important difference, and recommended
reporting the proportion of participants with this
degree of improvement.(46) Statistical analysts have
suggested potential problems with the use of percentage changes,(111) but the approach has clinical appeal.
One might alternatively specify a certain number of
points as the relevant change, or the percentage of
participants reaching some threshold pain level (e.g.,
pain score less than 3 out of 10).
An attractive option to the RTF was reporting the
“cumulative distribution function” of responses for
the treatment and control group. This is a continuous
plot of the proportion of patients at each scale score
who experience change at that level or better. This
amounts to calculating the percentage of responders
at each value of the outcome score. This approach
acknowledges the lack of consensus on the approach
for establishing a responder threshold, and provides
information for any given threshold.(84)
Composite outcome measures
The RTF also discussed the potential for use of
composite outcome measures. One member noted
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that it is common in studies of osteoarthritis to require
improvement in pain score and functional status and
global self-assessment before judging treatment successful. Similar combinations have been proposed for
evaluating back pain.(17,102)
Composite measures are often required in FDA
trials for drug or device approval. For example, “success” in trials of artificial disc replacement required
functional improvement of 15 points on the Oswestry
scale, improvement in quality of life on the SF-36,
proper radiographic placement, and absence of new
neurologic deficits or revision surgery.(124) Such
composites offer the potential advantage of defining
success in terms that are clearly clinically important,
and not merely statistically significant.
However, the RTF concluded that with the paucity
of data on performance of such composite measures
for low back pain, it could not make a recommendation
about composite outcome measures. Instead, this was
recommended as an important topic for future research.

Time frames for outcome measures
The RTF chose not to make specific recommendations for timing of outcome assessments because
appropriate timing would vary depending on an
intervention. For some treatments (e.g., analgesics
or spinal manipulation), the goal may be short-term
relief. For others, such as surgery, the goal is more
often long-term relief. For studying patients with
chronic pain, longer-term follow-up (e.g., at least
6-12 months) is generally preferred.
Adverse events
Reporting of adverse events was recognized as
an important outcome measure. Because the likely
adverse events vary enormously with the nature of
an intervention, the RTF did not make recommendations for reporting specific adverse events. There was
general agreement that for most intervention studies,
it would be desirable to specify certain adverse events
in advance and measure them prospectively, along
with open-ended reporting of unanticipated events.
Recommendation 5. Research on the Proposed
Standards
The RTF recommended new research to improve
prognostic stratification of patients with cLBP; refine
and test composite outcome measures for increasing
the clinical importance of study results; undertake
patient stakeholder assessment of relevant outcomes;
and further evaluate psychometric properties of the
minimal dataset.
Because the measures in the minimal dataset
will often not comprise the sole measures used in
a study, their widespread use will not only provide
researchers a standardized set of data, but will also
provide accumulating evidence for (or against) the
reliability, validity, and clinical utility of the RTF

recommendations. The potential for such an iterative approach to re-evaluate scientific measures of
chronic pain was successfully modeled in developing
Research Diagnostic Criteria for Temporomandibular
Disorders (TMD). An iterative scientific process has
successfully evolved the next generation of evidencebased measures for diagnosing and classifying the
most common subtypes of TMD, including physical,
behavioral and psychosocial domains.(99)
Beyond viewing the present set of recommendations as appropriate topics for future research, the RTF
identified several related knowledge gaps that limit
our ability to define and classify critical domains and
variables. These were seen as important topics for
which further research should be encouraged.

Prognosis
Improving prognostic stratification of patients
with cLBP is important clinically to help guide the
nature and intensity of therapy, and important for
researchers to adjust for confounding and to improve
comparability among studies. Recent work such as the
STarT Back project from the U.K. has made important
advances in this regard,(57-60) and others have systematically reviewed risk factors for the emergence of
chronic back pain.(30) However, the generalizability of
such studies to interventions and populations outside
of primary care remain uncertain. Other approaches
may be important for specific populations, or predicting specific treatment outcomes. Additional work in
this area might improve the ability to characterize
clinically important subgroups of patients with cLBP
and improve our “impact stratification”.
Composite outcome measures
An ongoing frustration has been the seeming lack
of progress in reducing back-related disability at
a population level. In part, this may be a result of
claiming treatment efficacy based on statistically
significant but clinically trivial results. More work is
needed to understand how certain outcome scores are
associated with major events such as return to work.
Composite outcome measures, such as requiring simultaneous improvement in pain, function, and global
self-assessment, may move us closer to important outcomes. However, more data are needed to determine
the performance of such measures in terms of validity,
reliability, responsiveness, and prognostic value.
Patient stakeholder assessment
Little work has addressed the outcomes judged
most important by patients with chronic low back
pain. Such outcomes may vary with demographic
features and diagnosis.
Psychometric properties of the proposed
minimal dataset
Extensive effort has been made to validate the PROMIS measures,(5,7,21,51,55,72,89,92,95) but there is modest
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information on their performance specifically in the
context of cLBP. One recent study suggested excellent
performance of the PROMIS physical function item
bank among patients with back and neck problems.(63)
Further data on the precision of the domains is important (e.g., the optimal number of items), as well as data
on responsiveness to change and sensitivity to small
differences. Creating a “cross-walk” of scores with
legacy measures such as the Oswestry and RolandMorris disability questionnaires is also important.

Recommendation 6. Dissemination of the
Report of the NIH Task Force on Research
Standards for Chronic Low Back Pain
With adoption of recommendations by the NIH
Pain Consortium, the RTF recommends dissemination
to the broad research community, including publication of a report in multiple professional journals and
presentations at professional meetings.
The NIH Pain Consortium has accepted the RTF
report (to view the full NIH approved RTF report on
Standards for Research on Chronic Low back Pain see:
www.painconsortium.nih.gov). The consortium is recommending that all NIH institutes and centers require
grant applications proposing clinical studies of cLBP
to utilize the research standards set forth in the RTF
report. Similarly, NIH encourages all other agencies
that fund research on cLBP to consider incorporating
these research standards for their respective awardees
or investigators, as appropriate. The RTF proposed to
disseminate these recommendations in professional
journals and presentations at scientific meetings.

DISCUSSION
Consistent with its charge from NIH, the RTF
strove to recommend standards for conducting research into the complex, intertwined factors that
influence the onset, natural history and clinical course
of cLBP. This remains one of the most important and
costly of all public health conditions affecting the U.S.
population. As adopted by NIH, these recommendations have the potential to standardize methods for
identifying cLBP research cases, describing research
subjects, and comparing published reports.
The new research standards should improve the
comparability of research studies on cLBP, facilitate
pooling data from multiple studies (e.g., for metaanalyses), and improve the ability to define phenotypes among patients with low back pain. These
standards will allow comparable core summary
statistics to be included in all published reports, without interfering with collection of specific measures
needed to address specific research questions.
After extended review and discussion, the RTF concluded that at the current state of scientific evidence
on cLBP, it was not realistic to create operationally

defined Research Diagnostic Criteria for subsets of
cLBP. While creation of research diagnostic criteria
has proven beneficial to research for some other conditions (e.g., temporomandibular joint disorders,(99)
Alzheimer’s Disease(98)), the multifactorial nature of
most cases of cLBP decreased enthusiasm for attempting to do so in this condition. However, creation of an
impact stratification and a uniform minimal dataset
will achieve many of the same goals.
In summary, the RTF has recommended a definition
of cLBP and proposed classifying it in terms of its
impact, in addition to any presumed pathoanatomic diagnosis. Impact is conceived as a combination of pain
intensity, interference with activities, and physical
function. The RTF has also recommended a uniform
minimal data set, with recommendations for medical
history, physical examination, diagnostic tests, and
self-report measures of physical function, depression,
and sleep disturbance, in addition to pain intensity
and interference. Finally, recommendations have been
made for reporting patient outcomes, further research,
and dissemination of the recommendations.
Any effort to standardize research methods is only
a starting point for further testing and refinement.
The final recommendations were seen as a first step
towards creating Standards for Research in cLBP. We
anticipate that further validation, refinement, and possible extension of these recommendations will require
years and the efforts of many investigators. Nonetheless, the RTF believes these recommendations can
advance the field, help to resolve controversies, and
facilitate future research addressing the prevalence
and incidence and genomic, neurologic, and other
mechanistic substrates of cLBP. Furthermore, it can
help to reveal the biologic-behavioral interfaces that
confound our present day understanding of cLBP and
its evidence-based management.
It is anticipated that the RTF recommendations will
become a dynamic document, and that the proposals
are likely to undergo continual improvement. The proposed research agenda should facilitate this evolution.
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